Fully integrated, pre-clinical stage biotechnology company developing therapeutics for the accessible treatment of psychiatric diseases
Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics
Diamond Therapeutics develops psilocybin based medicines while mitigating side effects
Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market
Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible
Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.
ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis
GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.
Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.
Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.
Orthogonal's mission is to give people access to nature’s most effective health solutions while setting the standard of a new “Farma”: Food as Medicine.
.
A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis
.
A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.
October 23-25, 2023 - San Francisco, California
Lindsay Hoover will speak at SOCAP Global 's annual conference on the following panel: "Impact Investment in Psychedelics: exploring new waters in mental health impact." This will be a moderated conversation, where participants will hear from experts about the potential impact of psychedelic medicine in mental health and wellbeing. Participants will hear from practitioners working in both the regulated and unregulated spaces of the psychedelics ecosystem.
SOCAP convenes the most engaged and diverse impact investing community in the world. For more than 15 years, the SOCAP conference has been the flagship event and leading convener in the impact economy, gathering more than 100,000 people since their first event. Find out more and register here.
November 11, 2023 - Zagreb, Croatia
Nepopularna psihologija is hosting the first multidisciplinary conference on psychedelics in Croatia, organised with the goal of raising awareness about scientific research on psychedelics and their potential application in medical and therapeutic contexts. Lectures will be given by scientists, experts, clinicians and therapists, and a roundtable discussion will be held on the state of attitudes and research on psychedelics in the balkan region.
Members of the public can join the conference as either an active participant or passive participant. Registration for passive participation ends on September 1st. Find out more and register here: https://nepopularna.org/forms-of-participation-and-conference-registration/
Donate to this ground-breaking conference here: https://www.mightycause.com/story/Croatia-Goes-Psychedelic
December 10-13, 2023 -Tel Aviv
Simeon Schnapper will be speaking at Israel's interdisciplinary international forum for exchanging ideas, unveiling innovations and training in the basics of psychedelic-assisted psychotherapy. Simeon will be featured in the Salon, "Making the Magic: In Search of Production Innovation to Meet the Challenges of the Psychedelics Supply Chain."
More information here: https://www.psychmedisrael.com/
Simeon Schnapper was interviewed for this article on the challenges facing the rapidly expanding psychedelics industry
Simeon Schnapper is among the major psychedelics VC & EFT directors who shared valuable insights at the Psychedelics Capital Conference (PCC)
How Awkn is navigating the tough market for investment capital
Psychedelics were the hot topic at the World Economic Forum 2022
How Awkn is navigating the tough market for investment capital
How Awkn is navigating the tough market for investment capital
He was the Canadian head of the world’s largest pot company. His next big bet? A rare fungus worth thousands a kilogram
Will Psychedelics Continue To Grow In 2021? Jeff Siegel Shares Insights And Strategies As More Companies Go Public
Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD
Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more
Lindsay Hoover will be speaking at SOCAP Global's annual conference on the following panel: "Impact Investment in Psychedelics: exploring new waters in mental health impact."
Simeon Schnapper spoke on the Business Track panel at the MIND Foundation's INSIGHT Conference in Berlin.
Simeon Schnapper spoke on the panel, "The Psychedelics Business Landscape: Are Companies Faltering or Failing, And Why?"
Leonard Pickard spoke about the underground history of LSD and its "overground future" at MAPS' fourth annual conference on the future of psychedelic medicine.
Lindsay Hoover spoke on two panels at MAPS' fourth annual conference on the future of psychedelic medicine.
Simeon Schnapper co-hosted a thought provoking discussion on the intersection of psychedelics, AI, and robotics.
Simeon Schnapper spoke at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida.
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at an interdisciplinary symposium at Ohio State University on the future of psychedelic research
William Leonard Pickard spoke at the first annual "Psychedelic Science and Spirituality Summit" in Stowe, Vermont
William Leonard Pickard spoke at Horizons Northwest's "Perspectives on Psychedelics" conference
Lindsay Hoover spoke at Horizons: The Psychedelic Business Forum, the largest and longest-running annual gathering of the psychedelic community in the world
Simeon Schnapper spoke on a panel discussing the intersection of psychedelic research, treatments, and investment
Simeon Schnapper on the tensions between philanthropic and for-profit investment, and the challenges and opportunities of this explosive new sector.
Political Importance of Ibogaine Development with Rick Doblin, JLS' Simeon Schnapper, and Daniel Callahan
Simeon Schnapper and Lindsay Hoover discuss investing in the psychedelic space and the developing ecosystem of this emerging industry.
William Leonard Pickard presented at a panel entitled: The Pathway to Federal Acceptance
Lindsay Hoover speaks on Consolidation in the Psychedelics Industry: What to Expect
William Leonard Pickard and Caleb O. Brown discuss promise and pitfalls in taking psychedelic medicine mainstream.
Lindsay Hoover on differentiating opportunities between private & public companies
Jeff Siegel on investing in the future of mental healthcare: psychedelics as an asset class
Simeon Schnapper moderates a panel on addressing mental health through emerging therapies.
Lindsay Hoover of JLS Fund: Psychedelics as Therapeutics: The Contribution of Game Heuristics
Watch Simeon Schnapper on Pysched, the show that explores psychedelics through political, social, and economic perspectives.
Stay up to speed with the world of psychedelics with our weekly updates. Sign up.